INTENDED FOR UK & IRELAND HEALTHCARE PROFESSIONALS

INTENDED FOR UK & IRELAND HEALTHCARE PROFESSIONALS

PRESCRIBING INFORMATION

Quinsair® (levofloxacin hemihydrate)
Key information
  • The first inhaled fluoroquinolonefor the management of chronic Pseudomonas aeruginosa infection in adults with cystic fibrosis2
  • Increases time to additional anti-pseudomonal antibiotic use while reducing exacerbation-related hospitalisations vs. tobramycin inhaled solution3*
  • Improves relative change in FEV1% predicted from baseline and quality of life vs. tobramycin inhaled solution3*
  • Ready-to-use ampoules with twice daily dosingand delivered in about 5 minutes by a modern nebuliser handset2,4
  • Generally well-tolerated1,3, with a safety profile similar to tobramycin inhaled solution3*

FEV1, forced expiratory volume in 1 second


* Multi-centre, randomised, non-inferiority study; 2.4 ml of 100 mg Quinsair, n=282.

1. Quinsair®, European Medicines Agency. Assessment Report 2015. EMA/CHMP/676680/2015;1-106
2. Quinsair® Summary of Product Characteristics. Available online at www.medicines.org.uk/emc/medicine/32009. Accessed March 2018.
3. Elborn JS, et al. J Cyst Fibros. 2015;14:507-14.
4. PARI eFlow Zirela patient information leaflet. Instructions for use. 2015.